Oramed Pharmaceuticals Inc. (ORMP) Price Target Analysis
Analyst Rating: Buy
Based on 8 analystsNo Target Data
ORMP trades at Wall Street's consensus target of —.
Current Price$4.60
Average Target—
Low—
Median—
High—
Analyst Target Range
Forward P/E2.0x
(Value)
PEG Ratio—
Implied Growth-11.9%
(Declining)
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes ORMP achieves its forward estimates and maintains a stable P/E multiple of 2.0x. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
ORMP Price Target Analysis
Updated July 6, 2026As of July 6, 2026, Oramed Pharmaceuticals Inc. (ORMP) has a Wall Street consensus price target of N/A, based on estimates from 8 covering analysts. The company has a market capitalization of $188M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ORMP trades at a trailing P/E of 3.1x and forward P/E of 2.0x. Analysts expect EPS to grow -11.9% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+38.6%
Industry Consensus
Avg Forward P/E
13.3x
(Value)
Peers with Coverage
9 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MNKDMannKind Corporation | $1.4B | $4.52 | $8.50 | +88.1% | Buy | — | 19 |
 NRXPNRx Pharmaceuticals, Inc. | $67M | $3.87 | — | — | — | — | — |
 PRAXPraxis Precision Medicines, Inc. | $9.2B | $318.52 | $589.00 | +84.9% | Buy | — | 16 |
 NVONovo Nordisk A/S | $224.1B | $50.43 | $45.00 | -10.8% | Buy | 2.3x | 39 |
 LLYEli Lilly and Company | $1.1T | $1210.50 | $1269.94 | +4.9% | Buy | 33.1x | 45 |
 SNYSanofi | $103.8B | $43.16 | $51.00 | +18.2% | Hold | 10.3x | 27 |
 VKTXViking Therapeutics, Inc. | $4.3B | $37.44 | $93.60 | +150.0% | Buy | — | 24 |
 AMGNAmgen Inc. | $201.9B | $374.15 | $352.50 | -5.8% | Buy | 16.7x | 38 |
 BMYBristol-Myers Squibb Company | $118.7B | $58.13 | $62.60 | +7.7% | Hold | 9.2x | 41 |
 PFEPfizer Inc. | $138.3B | $24.32 | $26.75 | +10.0% | Hold | 8.2x | 39 |
ORMP — Frequently Asked Questions
Quick answers to the most common questions about buying ORMP stock.
What is the ORMP stock price target for 2026?
The consensus price target for ORMP is $N/A, close to the current price of $4.6 (N/A% implied move). Based on 8 analyst estimates, the stock appears fairly valued near current levels.
Is ORMP a buy, sell, or hold?
ORMP has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is ORMP stock overvalued or undervalued?
With a forward P/E of 1.9913x, ORMP trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
How high can ORMP stock go?
The most bullish Wall Street analyst has a price target of $N/A for ORMP, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover ORMP stock?
ORMP is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ORMP stock forecast?
The 12-month ORMP stock forecast based on 8 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
What is ORMP's forward P/E ratio?
ORMP trades at a forward P/E ratio of 2.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 3.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy ORMP stock?
ORMP appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ORMP price targets vary so much?
ORMP analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare